CheckMyRecalls

Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release…

Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules USP

Published
13 May 2026
Units affected
165,761 90-count bottles
Agency
FDA
Country
United States

The hazard

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Duloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. by Towa Pharmaceutical Eurpoe S.L., Martorelles, (Barcelona), Spain, Dist. by. Breckenridge Pharmaceutical, Inc., Berkely Heights, NJ 07922, NDC 51991-748-90.

Brand / company
Breckenridge Pharmaceutical, Inc.
Codes / lots
Lot: 241069C, Exp 05/31/2027
Distribution
Nationwide in the USA
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 13 May 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.